Pan Cancer T secures €4.25M seed extension round We are delighted to announce the successful closing of Pan Cancer T’s €4.25 million seed extension round, which will accelerate development of our next-generation T cell therapies. See press release: https://t.ly/CjFGq This financing round will enable us to advance our lead TCR-T cell product, PCT1:CO-STIM, to the clinic for the treatment of triple negative breast cancer, and support progression of earlier-stage pipeline projects. It also provides a firm foundation to secure a Series A round within the coming year and seek business development partnerships with Biotech and Pharma collaborators to further develop our assets (including our TCR:CO-STIM platform that is applicable to other TCRs and tumour indications). We would like to welcome our new investor, InnovationQuarter, and thank our existing investors, Van Herk Ventures (Van Herk Groep), Thuja Capital, Swanbridge Capital and Erasmus MC O&O Holdings, for their continued support.
Pan Cancer T
Biotechnologisch onderzoek
Rotterdam, South Holland 1.043 volgers
Pan Cancer T is a biotechnology company developing T cell receptor (TCR) T-cell therapy for solid tumors.
Over ons
Pan Cancer T is a biotechnology spin-out (Erasmus MC, Rotterdam) focussed on the discovery and development of T cell receptor (TCR) T cell therapies. We exploit the 20 years of pioneering in adoptive T cell therapy as a springboard to breakthrough treatment of solid tumors. Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors, and make T cell therapy maximally accessible despite the tumor micro-environment challenges.
- Website
-
http://www.pancancer-t.com
Externe link voor Pan Cancer T
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 2-10 medewerkers
- Hoofdkantoor
- Rotterdam, South Holland
- Type
- Particuliere onderneming
- Opgericht
- 2020
Locaties
-
Primair
Routebeschrijving
Marconistraat 16
Rotterdam, South Holland 3029, NL
Medewerkers van Pan Cancer T
-
Reinout Hesselink, PhD
Accelerating Cell and Gene therapies to patients as Owner at R.H. Cell Therapy Consulting. Solving your Process and CMC problems by listening, not…
-
Dora Hammerl
Co-founder, VP R&D Pan Cancer T BV
-
Rachel Abbott
Chief Executive Officer at Pan Cancer T
-
Reno Debets
Professor in T-cell immunity and adoptive therapy of tumors
Updates
-
Our CEO, Rachel Abbott, and co-founder, Dora Hammerl, enjoyed chatting with Rotterdam Square recently about the benefits of being part of the Rotterdam ecosystem, our recent grant funding and the progress we are making developing next generation TCR-T cell therapies for solid cancer including triple negative breast cancer.
-
Pan Cancer T's CEO, Rachel Abbott is looking forward to participating in the EIT Health #Catapult finals at health.tech conference in Munich tomorrow!
🌟 Exciting news! The EIT Health Catapult finals are back at health.tech! 🏆 Join us June 5 -6 to witness the culmination of a year-long journey for nine outstanding life science and healthtech start-ups. Who will emerge as the next success story? 🔍 The Catapult programme has propelled European health start-ups to success by connecting them with top experts and international investors. 🤝 Meet our life science finalists: Celex Oncology Innovations Ltd Pan Cancer T POLYGON Therapeutics 🤝 Meet our healthtech finalists: Acorai Digistain® Dymium Five Lives nen Saphenus Medical Technology 🔎Learn more about the finalists: https://loom.ly/5kuRUA0 🌐 #EITHCatapult #HealthTech #LifeSciences #HealthcareInnovation
-
-
We are delighted to have been awarded this Dutch Cancer Society Public Private Partnership award, together with our co-founder Reno Debets, to help us develop next generation adoptive T cell products that are resistant to inhibitory macrophages in the hostile tumour microenvironment. #KWF #ErasmusMC #ErasmusMCCancerInstitute
Fantastic news and very honored to receive an award of 0.9 M Euro’s to develop T cell products that resist the immune-hostile microenvironment of breast cancer. Many thanks to the Dutch Cancer Society and their call for Public Private Partnerships for this generous support. Adoptive cellular therapy (ACT) is a successful form of immune treatment for blood cancers, yet the number of solid tumor patients benefiting from ACT is still limited. An immune-suppressive tumor microenvironment, often dominated by a subset of macrophages, is severely challenging T cell products to exercise long-term effects. In this new project, we will exploit gene editing to generate next generation T-cell products that overcome such immune suppression and demonstrate their clinical readiness to treat patients with Triple Negative Breast Cancer. This award was not possible without a great collaboration with co-PIs Dora Hammerl and Rachel Abbott from Pan Cancer T BV. Looking very much forward to move this project forward! #KWF #ErasmusMC #ErasmusMCCancerInstitute #PanCancerT https://lnkd.in/eX6ujR8i
New generation of immune cells against breast cancer - Amazing Erasmus MC
amazingerasmusmc.com
-
The 5 minute pitch we presented as part of the EIT Health Catapult 2024 semi-finals is now available to watch online until 15th February. Follow the link if you would like to hear how Pan Cancer T is developing next generation T cell therapies to treat solid cancers, starting with Triple Negative Breast Cancer. https://lnkd.in/exGhN33z Find us in the Life Science category.
🌟 Exciting News! 🚀 Our EIT Health Catapult Semifinalist pitches are now available! Meet the participants and explore a wave of Healthtech and Lifesciences innovations on our On-Demand platform for a limited time only. Stay ahead, uncover opportunities, and be part of the future of healthcare. 💡Join today: www.eithealthcatapult.com
Welcome to the Semifinals | EIT Health Catapult Semifinals
eithealthcatapult.com